Latest Results from an Ongoing First-in-Human Phase 1a/b Study of NX5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-Cell Malignancies
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2024）
关键词
CLL,NX-5948,BTK degrader,relapsed/refractory CLL,B-cell malignancies,BTK mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要